After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying off any staff “not deemed necessary to pursue strategic alternatives.” The ...
Carisma Therapeutics had already laid off 95% of its team earlier this year. Now, a Hail Mary merger proposal with another biotech has fallen through. The cell therapy macrophage biotech had just six ...
And the company, which develops cellular therapies aimed at fighting solid tumors, plans to expand its 37-person team by about 30% this year. Carisma Therapeutics President and CEO Steven Kelly.
PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan ...
PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly ...
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...
Baird has downgraded Carisma Therapeutics (NASDAQ:CARM) to neutral from outperform, citing a lack of near-term catalysts. The investment firm noted that Carisma (NASDAQ:CARM) has decided to pivot from ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Sesen Bio investor group last ...
“NextUp” is a weekly NextHealth PHL feature that highlights the local leaders, organizations and research shaping the Greater Philadelphia region’s life sciences ecosystem. Email qmuse@phillymag.com ...
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Ocugen), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results